Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 3,990 JPY | -2.87% | -2.94% | -6.12% | |
| Sales 2024 * | 1,534B 10.65B | Sales 2025 * | 1,717B 11.92B | Capitalization | 7,877B 54.71B |
|---|---|---|---|---|---|
| Net income 2024 * | 136B 946M | Net income 2025 * | 175B 1.22B | EV / Sales 2024 * | 4,69x |
| Net cash position 2024 * | 690B 4.79B | Net cash position 2025 * | 612B 4.25B | EV / Sales 2025 * | 4,23x |
| P/E ratio 2024 * | 58,1x | P/E ratio 2025 * | 44,4x | Employees | 17,435 |
| Yield 2024 * | 0,88% | Yield 2025 * | 1,11% | Free-Float | 97.03% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.87% | ||
| 1 week | -2.94% | ||
| Current month | -0.25% | ||
| 1 month | -2.01% | ||
| 3 months | -3.97% | ||
| 6 months | -15.82% | ||
| Current year | -6.12% |
1 week
3 933.00
4 215.00
1 month
3 896.004 215.00
Current year
3 566.005 162.00
1 year
3 566.005 162.00
3 years
1 981.005 162.00
5 years
1 092.335 162.00
10 years
518.675 162.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 2007 |
Hiroyuki Okuzawa
DFI | Director of Finance/CFO | 61 | 2017 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Noritaka Uji
CHM | Chairman | 74 | 2014 |
Sawako Nohara
BRD | Director/Board Member | 65 | 2019 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 2019 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 7 M€ | +0.93% | ||
| 4.54% | 9 M€ | +18.07% | ||
| 4.42% | 848 M€ | +7.56% | ||
| 4.42% | 108 M€ | +7.28% | - | |
| 4.42% | 25 M€ | +24.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 3,990 | -2.87% | 5 676 900 |
| 23-12-07 | 4,108 | -2.47% | 3,819,200 |
| 23-12-06 | 4,212 | +4.05% | 5,184,200 |
| 23-12-05 | 4,048 | +0.57% | 3,986,200 |
| 23-12-04 | 4,025 | -2.09% | 5,102,500 |
Delayed Quote Japan Exchange, December 08, 2023 at 01:00 am EST
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,108JPY
Average target price
5,330JPY
Spread / Average Target
+29.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.12% | 54 641 M $ | |
| +60.80% | 529 B $ | |
| +42.05% | 430 B $ | |
| -12.03% | 374 B $ | |
| -6.37% | 263 B $ | |
| -8.44% | 261 B $ | |
| -14.13% | 229 B $ | |
| +0.79% | 198 B $ | |
| -9.98% | 197 B $ | |
| -44.13% | 162 B $ |
